RecruitingPhase 1Phase 2NCT07346157

Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

PNOC044: Liothyronine (L-T3) in Combination With Bevacizumab, Irinotecan and Temozolomide (BIT) for Progressive or Relapsed Medulloblastoma (Cohort 1) or as Monotherapy for Medulloblastoma With Minimal Residual Disease (Cohort 2)

Sponsor

Sabine Mueller, MD, PhD

Enrollment

69 participants

Start Date

Aug 21, 2026

Study Type

INTERVENTIONAL

Conditions

Medulloblastoma Medulloblastoma, Childhood Medulloblastoma Recurrent

Summary

This is a Phase 1/Phase 2 study assessing liothyronine (L-T3) immunotherapy and in combination with standard chemotherapy (bevacizumab, irinotecan and temozolomide (BIT)) in children and young adults with medulloblastoma that is relapsed or progressive after standard upfront therapy.

Eligibility

Min Age: 1 YearMax Age: 25 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Bevacizumab, a drug called Irinotecan, and others for people with medulloblastoma, medulloblastoma recurrent, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 1 Year to 25 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.